Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tropisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 9/20 | 0.98 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 7/20 | 0.98 |
| ▸ | HTR3B known ✓ | O95264 | 7/20 | 0.98 |
| ▸ | HTR3D known ✓ | Q70Z44 | 7/20 | 0.98 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 7/20 | 0.98 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.98 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.98 |
| ▸ | CHRNG | P07510 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.98 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.98 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.98 |
| ▸ | CHRND | Q07001 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tropisetron SCHEMBL133873 | 1.00 | APEX1 (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL7375657 | 1.00 | APEX1 (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL6273985 | 1.00 | APEX1 (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL28012530 | 0.99 | APEX1 (0.98) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL463128 | 0.99 | HTR3A (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL17766649 | 0.99 | HTR3A (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL31061471 | 0.99 | HTR3A (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL29930627 | 0.99 | HTR3A (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL18297 | 0.99 | HTR3A (1.00) | APEX1RECQLHTR3AHTR3EHTR3B | |
| Tropisetron SCHEMBL29405651 | 0.99 | HTR3A (1.00) | APEX1RECQLHTR3AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| CN-119074698-A | Tropisetron long-acting slow-release transdermal patch and preparation method thereof | 烟台大学 | 2024-12-06 | — | — | CN | claimed |
| CN-118986874-A | Pharmaceutical composition, pharmaceutical preparation and preparation method of tropisetron hydrochloride oral solution | 南京海鲸药业股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | claimed |
| CN-110161149-B | Method for detecting impurity a-tropine in tropisetron hydrochloride injection | 福安药业集团宁波天衡制药有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-114617859-A | Tropisetron hydrochloride ethosome gel plaster and preparation method thereof | 烟台大学 | 2022-06-14 | — | — | CN | claimed |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | claimed |
| CN-216270928-U | A liquid medicine buffer for tropisetron hydrochloride | 济南康桥医药科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114129527-A | Miniature tablet and preparation method and preparation thereof | 北京微智瑞医药科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-215195662-U | A liquid medicine filter equipment for tropisetron hydrochloride | 济南康桥医药科技有限公司 | 2021-12-17 | — | — | CN | claimed |
| CN-102584815-A | Method for preparing tropisetron hydrochloride on large scale | HUNAN KAMP INST FOR MEDICAL RES | 2012-07-18 | — | — | CN | claimed |
| CN-102532128-A | Synthetic method of tropisetron and prepare method of hydrochloric acid tropisetron | UNIV PEKING FOUNDER GROUP CO | 2012-07-04 | — | — | CN | claimed |
| CN-102367252-A | Tropisetron hydrochloride compound | TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD | 2012-03-07 | — | — | CN | claimed |
| CN-102351857-A | Tropiseiron hydrochloride compound | TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD | 2012-02-15 | — | — | CN | claimed |
| CN-101787021-B | High-purified tropisetron hydrochloride compound | MING WANG | 2011-08-24 | — | — | CN | claimed |
| CN-102020653-A | New application of amino perhydrogenated quinazoline compound and derivative preparation thereof for improving drug effects of anticancer drugs | JIANGSU HONGMIANTIAN PHARMACEUTICAL CO LTD | 2011-04-20 | — | — | CN | claimed |
| CN-101787021-A | High-purified tropisetron hydrochloride compound | MING WANG | 2010-07-28 | — | — | CN | claimed |
| CN-1682721-A | Tropisetron hydrochloride oral disintegration tablet preparation and its preparing method | WANG LIQIANG (CN) | 2005-10-19 | — | — | CN | claimed |
| US-20030104066-A1 | Easy-to-take granules | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-06-05 | — | — | US | claimed |
| EP-1269995-A1 | EASY-TO-TAKE GRANULE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | HTR3A 4/4885HTR3E 8/4885HTR3B 12/4885 |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | EYA3, RB1, ALDH1A2 | HTR3A 2141/4885HTR3E 1566/4885HTR3B 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.